Stock KTRA KINTARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Kintara Therapeutics, Inc.

Equities

KTRA

US49720K2006

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-11 pm EDT 		5-day change 1st Jan Change
0.2734 USD +0.70% Intraday chart for Kintara Therapeutics, Inc. -8.87% +61.20%
Jul. 02 Kintara Therapeutics, Inc. and TuHura Biosciences, Inc. Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones CI
Jun. 03 TuHura Biosciences, Inc. and Kintara Therapeutics, Inc. Announces Positive Results from Phase 1b Trial of IFx-2.0 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
AQ
Basal Cell Carcinoma Pipeline 2024 | PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma
AQ
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline near Term Milestones
AQ
Kintara Therapeutics, Inc. and TuHura Biosciences, Inc. Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
CI
TuHura Biosciences, Inc. and Kintara Therapeutics, Inc. Announces Positive Results from Phase 1b Trial of IFx-2.0
CI
Kintara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
CI
Kintara Therapeutics : Shareholder Meeting - Form 8-K
PU
TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Kintara Therapeutics : TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - Form 8-K
PU
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA
PR
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA
BU
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Sector Update: Health Care
MT
Top Midday Gainers
MT
Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURA
PR
KTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to Shareholders
BU
Transcript : Kintara Therapeutics, Inc., TuHURA Biosciences, Inc. - M&A Call
TuHURA Biosciences, Inc. entered into a definitive agreement to acquire Kintara Therapeutics, Inc. in a reverse merger transaction.
CI
TuHURA Biosciences, Inc. agreed to acquire Kintara Therapeutics, Inc. in a reverse merger transaction.
CI
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KTRA Stock
  4. News Kintara Therapeutics, Inc.